Virtual drug design platform to accelerate drug discovery

pharmafile | February 17, 2022 | News story | Business Services  

The Cambridge Crystallographic Data Centre (CCDC) announced a strategic partnership with Dassault Systemes to advance bioscience innovation with a cloud-based virtual screening solution.

The collaboration will interate GOLD – CCDC’s protein-ligand docking software for expert drug discovery – with Dassault Systemes’ BIOVIA therapeutics design software.

“This partnership cements a long-established and productive relationship between Dassault Systèmes and its BIOVIA applications and CCDC,” said Dr Jürgen Harter, CEO of CCDC. “GOLD on the 3DEXPERIENCE platform will empower even more researchers with the best of science to accelerate discovery using their proven processes. We’re excited to help advance the role of cloud-based, high-throughput virtual screening in the development of critical therapeutics.”

CCDC’s GOLD is a protein-ligand docking software for virtual screening, which predicts binding modes of active molecules. The integration of GOLD with BIOVIA therapeutics design software on the 3DEXPERIENCE platform will provide a new option for chemists to accelerate drug discovery.

In silico drug design is moving from discrete, classical modelling applications to more complete and unified solutions,” said Jason Benedict, Vice President of Research and Development, BIOVIA, Dassault Systèmes.

The 3DEXPERIENCE platform is a collaborative environment which aims to give businesses and people to innovate, and create products and services using virtual experiences. It provides a real-time view of business activity and ecosystem, connecting people, ideas, and data. The platform also acts as a marketplace, or a trading platform. That connects service providers and buyers.

Lina Adams

Related Content

No items found

Latest content